

# SAFETY DATA SHEET



## Alendronate / Vitamin D Formulation



Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Alendronate / Vitamin D Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

|  |  |
|--|--|
| Acute toxicity, Category 4                                     | H302: Harmful if swallowed.  |
| Skin irritation, Category 2                                    | H315: Causes skin irritation.  |
| Serious eye damage, Category 1                                 | H318: Causes serious eye damage.   |
| Reproductive toxicity, Category 2                              | H361d: Suspected of damaging the unborn child.                           |
| Specific target organ toxicity - single exposure, Category 3   | H335: May cause respiratory irritation.                                  |
| Specific target organ toxicity - repeated exposure, Category 2 | H373: May cause damage to organs through prolonged or repeated exposure. |

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
 Date of first issue: 15.10.2014

Hazard statements : H302 Harmful if swallowed.  
 H315 Causes skin irritation.  
 H318 Causes serious eye damage.  
 H335 May cause respiratory irritation.  
 H361d Suspected of damaging the unborn child.  
 H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**  
 P201 Obtain special instructions before use.  
 P260 Do not breathe dust.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Alendronate

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

| Chemical name  | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|----------------|---|---|--------------------------|
| Alendronate    | 121268-17-5   | Acute Tox. 4; H302<br>Skin Irrit. 2; H315<br>Eye Dam. 1; H318<br>Repr. 2; H361d<br>STOT SE 3; H335<br>STOT RE 2; H373<br>(Bone, Stomach,<br>Kidney) | >= 20 - < 30             |
| Colecalciferol | 67-97-0<br>200-673-2                                  | Acute Tox. 2; H300<br>Acute Tox. 2; H330  | >= 0,025 - < 0,1         |

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

|  |              |   |
|--|--------------|---|
|  | 603-180-00-4 | Acute Tox. 2; H310<br>STOT RE 1; H372<br>(Kidney, Blood,<br>Bone)<br>Aquatic Chronic 4;<br>H413 |
|--|--------------|---|

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Harmful if swallowed.  
Causes skin irritation.  
Causes serious eye damage.  
May cause respiratory irritation.  
Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Phosphorus compounds  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | <p>Static electricity may accumulate and ignite suspended dust causing an explosion.</p> <p>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.</p>   |
| Local/Total ventilation | : | <p>If sufficient ventilation is unavailable, use with local exhaust ventilation.</p>  |
| Advice on safe handling | : | <p>Do not get on skin or clothing.</p> <p>Do not breathe dust.</p> <p>Do not swallow.</p> <p>Do not get in eyes.</p> <p>Wash skin thoroughly after handling.</p> <p>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</p> <p>Keep container tightly closed.</p> <p>Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.</p> <p>Minimize dust generation and accumulation.</p> <p>Keep container closed when not in use.</p> <p>Keep away from heat and sources of ignition.</p> <p>Take precautionary measures against static discharges.</p> <p>Do not eat, drink or smoke when using this product.</p> <p>Take care to prevent spills, waste and minimize release to the environment.</p> |
| Hygiene measures        | : | <p>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.</p> <p>The effective operation of a facility should include review of</p>   |

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

| Components  | CAS-No.     | Value type (Form of exposure) | Control parameters           | Basis    |
|---|-------------|-------------------------------|------------------------------|----------|
| Cellulose   | 9004-34-6   | OEL-RL                        | 10 mg/m <sup>3</sup>         | ZA OEL   |
| Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents |             |                               |                              |          |
| Alendronate   | 121268-17-5 | TWA                           | 20 µg/m <sup>3</sup> (OEB 3) | Internal |
|   |             | Wipe limit                    | 200 µg/100 cm <sup>2</sup>   | Internal |
| Colecalciferol  | 67-97-0     | TWA                           | 5 µg/m <sup>3</sup> (OEB 4)  | Internal |
|   |             | Wipe limit                    | 50 µg/100 cm <sup>2</sup>    | Internal |

**8.2 Exposure controls****Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

|                          |   |   |
|--------------------------|---|---|
| Remarks                  | : | Consider double gloving.  |
| Skin and body protection | : | Work uniform or laboratory coat.<br>Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.<br>Use appropriate degowning techniques to remove potentially contaminated clothing. |
| Respiratory protection   | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  |
| Filter type              | : | Particulates type (P)   |

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

|  |   |   |
|--|---|---|
| Appearance                                       | : | powder  |
| Colour   | : | off-white   |
| Odour  | : | odourless   |
| Odour Threshold                                  | : | No data available   |
| pH   | : | No data available   |
| Melting point/freezing point                     | : | No data available   |
| Initial boiling point and boiling range          | : | No data available   |
| Flash point                                      | : | Not applicable  |
| Evaporation rate                                 | : | Not applicable  |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapour pressure                                  | : | Not applicable  |
| Relative vapour density                          | : | Not applicable  |
| Relative density                                 | : | No data available   |
| Density  | : | No data available   |
| Solubility(ies)                                  |   |   |
| Water solubility                                 | : | No data available   |
| Partition coefficient: n-octanol/water           | : | Not applicable  |
| Auto-ignition temperature                        | : | No data available   |

# SAFETY DATA SHEET



## Alendronate / Vitamin D Formulation



Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

---

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids) : No data available

Particle size : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Harmful if swallowed.

#### Product:

Acute oral toxicity : Acute toxicity estimate: 1.965 mg/kg



## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

Method: Calculation method

**Components:****Alendronate:**

|                           |   |                                 |
|---------------------------|---|---------------------------------|
| Acute oral toxicity       | : | LD50 (Rat): 552 - 626 mg/kg     |
|                           |   | LD50 (Mouse): 966 - 1.280 mg/kg |
| Acute inhalation toxicity | : | Remarks: No data available      |
| Acute dermal toxicity     | : | Remarks: No data available      |

**Colecalciferol:**

|                           |   |   |
|---------------------------|---|---|
| Acute oral toxicity       | : | LD50 (Rat, male): 35 mg/kg                                    |
| Acute inhalation toxicity | : | Acute toxicity estimate: 0,05 mg/l                            |
|                           |   | Exposure time: 4 h  |
|                           |   | Test atmosphere: dust/mist                                    |
|                           |   | Method: Expert judgement                                      |
| Acute dermal toxicity     | : | Acute toxicity estimate: 50 mg/kg<br>Method: Expert judgement |

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Alendronate:**

|         |   |                        |
|---------|---|------------------------|
| Species | : | Rabbit                 |
| Remarks | : | Severe skin irritation |

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****Alendronate:**

|         |   |                   |
|---------|---|-------------------|
| Species | : | Rabbit            |
| Result  | : | Severe irritation |

**Colecalciferol:**

|         |   |                   |
|---------|---|-------------------|
| Species | : | Rabbit            |
| Result  | : | No eye irritation |

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Alendronate:**

|         |   |                   |
|---------|---|-------------------|
| Remarks | : | No data available |
|---------|---|-------------------|

**Colecalciferol:**

|                 |   |                          |
|-----------------|---|--------------------------|
| Test Type       | : | Maurer optimisation test |
| Exposure routes | : | Skin contact             |
| Species         | : | Guinea pig               |
| Result          | : | negative                 |

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Alendronate:**

|                       |   |   |
|-----------------------|---|---|
| Genotoxicity in vitro | : | Test Type: Alkaline elution assay<br>Test system: rat hepatocytes<br>Result: negative   |
|                       | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Metabolic activation: with and without metabolic activation<br>Result: negative |
|                       | : | Test Type: In vitro mammalian cell gene mutation test<br>Result: negative   |
|                       | : | Test Type: Chromosomal aberration<br>Test system: Chinese hamster ovary cells<br>Result: equivocal                                    |
| Genotoxicity in vivo  | : | Test Type: Chromosomal aberration<br>Species: Mouse<br>Result: negative   |

**Colecalciferol:**

|                       |   |  |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Method: OECD Test Guideline 471<br>Result: equivocal   |
|                       | : | Test Type: In vitro mammalian cell gene mutation test<br>Method: OECD Test Guideline 476<br>Result: negative |
|                       | : | Test Type: Chromosome aberration test in vitro<br>Method: OECD Test Guideline 473<br>Result: negative        |
| Genotoxicity in vivo  | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo)   |

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

|  |                                    |   |
|--|------------------------------------|---|
|  |                                    | cytogenetic assay)<br>Species: Rat<br>Application Route: Ingestion<br>Method: OECD Test Guideline 474<br>Result: negative |
|  |                                    | Test Type: In vivo mammalian alkaline comet assay<br>Species: Rat<br>Application Route: Ingestion<br>Result: positive     |
|  | Germ cell mutagenicity- Assessment | : Weight of evidence does not support classification as a germ cell mutagen.  |

**Carcinogenicity**

Not classified based on available information.

**Components:****Alendronate:**

|  |                   |  |
|--|-------------------|--|
|  | Species           | : Rat, male  |
|  | Application Route | : Oral   |
|  | Exposure time     | : 2 Years  |
|  |                   | : 1 mg/kg body weight  |
|  |                   | : 3,75 mg/kg body weight   |
|  | Target Organs     | : Thyroid  |
|  | Remarks           | : The mechanism or mode of action may not be relevant in humans. |

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Alendronate:**

|  |                               |  |
|--|-------------------------------|--|
|  | Effects on fertility          | : Test Type: Fertility<br>Species: Rat, male and female<br>Application Route: Oral<br>Fertility: NOAEL: 5 mg/kg body weight<br>Result: Animal testing did not show any effects on fertility.   |
|  | Effects on foetal development | : Test Type: Development<br>Species: Rat, female<br>Application Route: Oral<br>Developmental Toxicity: LOAEL: 1 - 15 mg/kg body weight<br>Symptoms: Reduced number of viable fetuses, Reduced body weight, Skeletal malformations<br>Result: Embryotoxic effects and adverse effects on the offspring were detected. |
|  |                               | Test Type: Development<br>Species: Rabbit, female<br>Application Route: Oral<br>Developmental Toxicity: NOAEL: 40 mg/kg body weight  |

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

Result: No adverse effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

May cause respiratory irritation.

**Components:****Alendronate:**

Assessment : May cause respiratory irritation.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Alendronate:**

Target Organs : Bone, Stomach, Kidney  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Colecalciferol:**

Exposure routes : Ingestion  
Target Organs : Kidney, Blood, Bone  
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Alendronate:**

Species : Rat  
NOAEL : 2,5 mg/kg  
LOAEL : > 2,5 mg/kg  
Application Route : Intravenous  
Exposure time : 53 Weeks  
Target Organs : Stomach

Species : Dog  
LOAEL : 0,01 mg/kg  
Application Route : Intravenous  
Exposure time : 3 yr  
Target Organs : Stomach, Bone, Kidney

Species : Dog  
NOAEL : 2 mg/kg  
LOAEL : 4 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Kidney

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

**Colecalciferol:**

Species : Rat  
NOAEL : 0,06 mg/kg  
LOAEL : 0,3 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Method : OECD Test Guideline 408

**Aspiration toxicity**

Not classified based on available information.

**Components:****Alendronate:**

|| Not applicable

**Experience with human exposure****Components:****Alendronate:**

Inhalation : Symptoms: respiratory tract irritation  
Skin contact : Symptoms: Severe irritation, skin blistering  
Eye contact : Symptoms: Severe irritation  
Ingestion : Symptoms: Gastrointestinal disturbance, musculoskeletal pain

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Alendronate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 27 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
  
LC50 (Oncorhynchus mykiss (rainbow trout)): > 1.000 mg/l  
Exposure time: 96 h  
Method: FDA 4.11  
  
Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 170 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
  
Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
  
NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l  
Exposure time: 72 h

## Alendronate / Vitamin D Formulation

Version 6.0      Revision Date: 06.04.2024      SDS Number: 22066-00023      Date of last issue: 26.09.2023  
Date of first issue: 15.10.2014

Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC: 1,1 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

LOEC: 1,9 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 4,7 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

**Colecalciferol:**

Toxicity to fish : LL50 (Danio rerio (zebra fish)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EL50 (Scenedesmus capricornutum (fresh water algae)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

**12.2 Persistence and degradability****Components:****Alendronate:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 70,3 %  
Exposure time: 7 d

Stability in water : Degradation half life (DT50): 375 d  
Method: OECD Test Guideline 111

**Colecalciferol:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: <= 7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

**12.3 Bioaccumulative potential****Components:****Alendronate:**

|  |   |                |
|--|---|----------------|
| Partition coefficient: n-octanol/water | : | log Pow: -1,73 |
|--|---|----------------|

**Colecalciferol:**

|  |   |   |
|--|---|---|
| Partition coefficient: n-octanol/water | : | log Pow: > 6,2<br>Method: OECD Test Guideline 107 |
|--|---|---|

**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

|            |   |  |
|------------|---|--|
| Assessment | : | This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. |
|------------|---|--|

**12.6 Other adverse effects****Product:**

|                                |   |   |
|--------------------------------|---|---|
| Endocrine disrupting potential | : | The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. |
|--------------------------------|---|---|

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

|                        |   |   |
|------------------------|---|---|
| Product                | : | Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.  |

**SECTION 14: Transport information****14.1 UN number**

|     |   |                                   |
|-----|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.2 UN proper shipping name**

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.3 Transport hazard class(es)**

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

**14.4 Packing group**

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA (Cargo) : Not regulated as a dangerous good  
IATA (Passenger) : Not regulated as a dangerous good

**14.5 Environmental hazards**

Not regulated as a dangerous good

**14.6 Special precautions for user**

Not applicable

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

---

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined



## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

---

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

---

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H300 : Fatal if swallowed.  
 H302 : Harmful if swallowed.  
 H310 : Fatal in contact with skin.  
 H315 : Causes skin irritation.  
 H318 : Causes serious eye damage.  
 H330 : Fatal if inhaled.  
 H335 : May cause respiratory irritation.  
 H361d : Suspected of damaging the unborn child.  
 H372 : Causes damage to organs through prolonged or repeated exposure.  
 H373 : May cause damage to organs through prolonged or repeated exposure.  
 H413 : May cause long lasting harmful effects to aquatic life.

**Full text of other abbreviations**

Acute Tox. : Acute toxicity  
 Aquatic Chronic : Long-term (chronic) aquatic hazard  
 Eye Dam. : Serious eye damage  
 Repr. : Reproductive toxicity  
 Skin Irrit. : Skin irritation  
 STOT RE : Specific target organ toxicity - repeated exposure  
 STOT SE : Specific target organ toxicity - single exposure  
 ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits  
 ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-

## Alendronate / Vitamin D Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 26.09.2023  |
| 6.0     | 06.04.2024     | 22066-00023 | Date of first issue: 15.10.2014 |

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

|               |       |
|---------------|-------|
| Acute Tox. 4  | H302  |
| Skin Irrit. 2 | H315  |
| Eye Dam. 1    | H318  |
| Repr. 2       | H361d |
| STOT SE 3     | H335  |
| STOT RE 2     | H373  |

**Classification procedure:**

|                    |
|--------------------|
| Calculation method |
| Calculation method |
| Calculation method |
| Calculation method |
| Calculation method |
| Calculation method |

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN